Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / MSCLF - Satellos Bioscience: Promising Novel Treatment For Duchenne Muscular Dystrophy


MSCLF - Satellos Bioscience: Promising Novel Treatment For Duchenne Muscular Dystrophy

2025-09-02 09:37:25 ET

Toronto-based Satellos Bioscience (MSCL.TSX, MSCLF.OTCQB) is a clinical-stage small molecule development company focused on restoring natural muscle repair and regeneration for degenerative muscle diseases.

Its proprietary discovery platform, MyoReGenX, identifies, classifies and confirms regenerative deficits in serious muscle diseases. The platform can recreate the specialized muscle stem cell niche in vitro, which enables Satellos to identify and confirm drug targets, and test drug candidates for their ability to restore muscle stem cell repair mechanisms that have been impaired by genetic mutations, disease or injury....

For further details see:

Satellos Bioscience: Promising Novel Treatment For Duchenne Muscular Dystrophy

Stock Information

Company Name: Satellos Bioscience Inc.
Stock Symbol: MSCLF
Market: OTC
Website: satellos.com

Menu

MSCLF MSCLF Quote MSCLF Short MSCLF News MSCLF Articles MSCLF Message Board
Get MSCLF Alerts

News, Short Squeeze, Breakout and More Instantly...